The Drug Discovery Toxicology Specialty Section of SOT has selected Professor Ruth Roberts as the recipient of their Paper of the Year Award for 2021.
The Paper of the Year Award was created to highlight a scientific achievement in the field of Discovery Toxicology.
Ruth A Roberts, Richard A Campbell, Phumzile Sikakana, Claire Sadler, Mark Osier, Yili Xu, Joy Y Feng, Michael Mitchell, Roman Sakowicz, Anne Chester, Eric Paoli, Jianhong Wang, Leigh Ann Burns-Naas, Species-Specific Urothelial Toxicity With an Anti-HIV Noncatalytic Site Integrase Inhibitor (NCINI) Is Related to Unusual pH-Dependent Physicochemical Changes, Toxicological Sciences, Volume 183, Issue 1, September 2021, Pages 105–116, https://doi.org/10.1093/toxsci/kfab073 (the paper is open access download here).
The paper had previously been chosen for the September Issue ToxSpotlight in Toxicological Sciences, the official SOT journal.
Ruth commented, “I would like to thank the DDTSS for selecting our paper for this great honour, especially since it highlights the detective work together with the extensive collaboration needed to unravel the mechanism behind unusual toxicological findings.”
Ruth and her leading co-author Leigh Ann Burns-Naas will receive their recognition plaque at the 61st Society of Toxicology Annual Meeting Drug Discovery Toxicology Specialty Section (DDTSS) reception.
ApconiX is looking forward to attending and exhibiting at SOT this year.
The Drug Discovery Toxicology Specialty Section:
The Drug Discovery Toxicology Specialty Section (DDTSS) provides a forum for discussion of emerging technologies, predictive toxicology, safety pharmacology, target validation, and safety assessment in a discovery research environment. SOT has 29 Specialty Sections.
DDTSS is a specialty section created to fulfil the growing need for incorporating predictive and integrative toxicological approaches early in drug discovery and development. Early application of these approaches is the key to identifying potential liabilities and providing necessary perspective that helps reduce attrition of drug candidates at later stages of the process. The overarching goal is to provide an integrated understanding of a drug candidate’s liabilities prior to its advancement into non-clinical development and clinical evaluation. This specialty section seeks to foster discussion and provide guidance around appropriate application of technologies and approaches that may refine or compliment traditional animal-based toxicology models. It also aims to identify gaps in novel and emerging technologies that require further development and application.